Intervention Review

You have free access to this content

Antiamoebic drugs for treating amoebic colitis

  1. Maria Liza M Gonzales1,*,
  2. Leonila F Dans2,
  3. Elizabeth G Martinez1

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 15 APR 2009

Assessed as up-to-date: 4 DEC 2008

DOI: 10.1002/14651858.CD006085.pub2

Database Title

Additional Information

How to Cite

Gonzales MLM, Dans LF, Martinez EG. Antiamoebic drugs for treating amoebic colitis. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD006085. DOI: 10.1002/14651858.CD006085.pub2.

Author Information

  1. 1

    College of Medicine-Philippine General Hospital, University of the Philippines, Department of Pediatrics, Manila, National Capital Region, Philippines

  2. 2

    Philippine General Hospital, University of the Philippines, Departments of Pediatrics and Clinical Epidemiology, Manila, National Capital Region, Philippines

*Maria Liza M Gonzales, Department of Pediatrics, College of Medicine-Philippine General Hospital, University of the Philippines, Taft Avenue, Manila, National Capital Region, 1000, Philippines. lizmgonzales@yahoo.com.

Publication History

  1. Publication Status: New
  2. Published Online: 15 APR 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (59K)Standard (867K)Full (1414K)
[Figure 1]
Figure 1. Alternative drug vs metronidazole: clinical failure 15 to 60 days after end of treatment.
[Figure 2]
Figure 2. Alternative drug vs metronidazole: parasitological failure 15 to 60 days after end of treatment.
[Figure 3]
Figure 3. Combination regimen vs monotherapy: parasitological failure 1 to 14 days after end of treatment, subgrouped by intervention.
[Figure 4]
Figure 4. Funnel plot. Alternative drug vs metronidazole: parasitological failure 15 to 60 days after end of treatment.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Alternative drug vs metronidazole, Outcome 1 Clinical failure: 1 to 14 days after end of treatment.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Alternative drug vs metronidazole, Outcome 2 Clinical failure: 15 to 60 days after end of treatment.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Alternative drug vs metronidazole, Outcome 3 Parasitological failure: 1 to 14 days after end of treatment.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Alternative drug vs metronidazole, Outcome 4 Parasitological failure: 15 to 60 days after end of treatment.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Alternative drug vs metronidazole, Outcome 5 Relapse (ornidazole).
[Analysis 1.6]
Analysis 1.6. Comparison 1 Alternative drug vs metronidazole, Outcome 6 Adverse events.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Any antiamoebic drug vs placebo, Outcome 1 Clinical failure: 1 to 14 days after end of treatment.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Any antiamoebic drug vs placebo, Outcome 2 Parasitological failure: 1 to 14 days after end of treatment.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Any antiamoebic drug vs placebo, Outcome 3 Other adverse events.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Combination regimen vs monotherapy, Outcome 1 Clinical failure: 1 to 14 days after end of treatment.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Combination regimen vs monotherapy, Outcome 2 Parasitological failure: 1 to 14 days after end of treatment.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Single dose regimen vs longer regimen, Outcome 1 Clinical failure: 1 to 14 or 15 to 60 days after end of treatment, combined.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Single dose regimen vs longer regimen, Outcome 2 Parasitological failure: 1 to 14 days after end of treatment.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Other antiamoebic drug comparisons, Outcome 1 Clinical failure: 1 to 14 days after end of treatment.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Other antiamoebic drug comparisons, Outcome 2 Parasitological failure: 1 to 14 days after end of treatment.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Subgroup analyses: alternative drug vs metronidazole, Outcome 1 Parasitological failure 15 to 60 days after end of treatment, by clinical category.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Subgroup analyses: alternative drug vs metronidazole, Outcome 2 Parasitological failure 15 to 60 days after end of treatment, by age group.
[Analysis 6.3]
Analysis 6.3. Comparison 6 Subgroup analyses: alternative drug vs metronidazole, Outcome 3 Parasitological failure 15 to 60 days after end of treatment, single or mixed intestinal infection.
[Analysis 6.4]
Analysis 6.4. Comparison 6 Subgroup analyses: alternative drug vs metronidazole, Outcome 4 Parasitological failure 15 to 60 days after end of treatment, by criteria.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Subgroup analyses: any antiamoebic drug vs placebo, Outcome 1 Parasitological failure 1 to 14 days after end of treatment, by clinical category.
[Analysis 7.2]
Analysis 7.2. Comparison 7 Subgroup analyses: any antiamoebic drug vs placebo, Outcome 2 Clinical failure 1 to 14 days after end of treatment, by age group.
[Analysis 7.3]
Analysis 7.3. Comparison 7 Subgroup analyses: any antiamoebic drug vs placebo, Outcome 3 Parasitological failure 1 to 14 days after end of treatment, by age group.
[Analysis 8.1]
Analysis 8.1. Comparison 8 Subgroup analyses: combination regimen vs monotherapy, Outcome 1 Clinical failure: 1 to 14 days after end of treatment, by intervention.
[Analysis 8.2]
Analysis 8.2. Comparison 8 Subgroup analyses: combination regimen vs monotherapy, Outcome 2 Parasitological failure: 1 to 14 days after end of treatment, by intervention.
[Analysis 9.1]
Analysis 9.1. Comparison 9 Subgroup analyses: any single dose regimen vs longer regimen, Outcome 1 Parasitological failure: 1 to 14 days after end of treatment, by intervention.
View Full Article (HTML) Summary (59K)Standard (867K)Full (1414K)